Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.90 |
| ▸ | HTT | P42858 | 1/20 | 0.90 |
| ▸ | HPGD | P15428 | 7/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MLYCD | O95822 | 3/20 | 0.63 |
| ▸ | CNR1 | P21554 | 2/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271078 | 0.98 | MEN1 (0.87) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL11300473 | 0.98 | MEN1 (0.87) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL3460184 | 0.98 | MEN1 (0.87) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL4406614 | 0.96 | MEN1 (0.96) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL19226469 | 0.92 | KMT2A (0.82) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL15317660 | 0.87 | HPGD (0.88) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL17886770 | 0.86 | HPGD (0.86) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL4548015 | 0.86 | HPGD (1.00) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL15317655 | 0.86 | MEN1 (0.78) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL10202499 | 0.85 | L3MBTL3 (0.77) | MEN1KMT2AALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-55049350-A | — | — | None | — | — | JP | disclosed |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-07-18 | — | — | US | disclosed |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-07-18 | — | — | US | disclosed |
| EP-3166640-B1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-06-14 | — | — | EP | disclosed |
| US-20230136177-A1 | IMMUNOMODULATING O-HET/ARYL AZALIDES | ZOETIS SERVICES LLC | 2023-05-04 | — | — | US | disclosed |
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220251212-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-08-11 | — | — | US | disclosed |
| US-20220204641-A1 | ANTI-CD20 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-06-30 | — | — | US | disclosed |
| US-7667036-B2 | MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders | TEIJIN PHARMA LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| JP-S5549350-A | N-SUBSTITUTED BENZANILIDE AND FUNGICIDE COMPRISING IT | KUMIAI CHEM IND CO LTD | 1980-04-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | MEN1 4175/4885KMT2A 1279/4885ALDH1A1 3662/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | MEN1 4047/4885KMT2A 1296/4885ALDH1A1 3235/4885 |
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, HK1 | MEN1 929/4885KMT2A 3655/4885ALDH1A1 3279/4885 |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | EGFR, ERBB3, ERBB2 | MEN1 2661/4885KMT2A 2217/4885ALDH1A1 2863/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | MEN1 4047/4885KMT2A 1296/4885ALDH1A1 3235/4885 |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ASGR1, HAVCR2, FCGR2A | MEN1 3890/4885KMT2A 1891/4885ALDH1A1 1746/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | MEN1 4047/4885KMT2A 1296/4885ALDH1A1 3235/4885 |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | MEN1 941/4885KMT2A 3224/4885ALDH1A1 1270/4885 |
| US-20230136177-A1 | IMMUNOMODULATING O-HET/ARYL AZALIDES | IL2, MALT1, IL2RA | MEN1 2286/4885KMT2A 1520/4885ALDH1A1 276/4885 |
| US-20220204641-A1 | ANTI-CD20 COMBINATIONS FOR TREATING TUMORS | CD209, CD68, CD47 | MEN1 1056/4885KMT2A 756/4885ALDH1A1 2619/4885 |
| US-20220251212-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | PDCD1LG2, CD274, PDCD1 | MEN1 1846/4885KMT2A 850/4885ALDH1A1 963/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | MEN1 4233/4885KMT2A 998/4885ALDH1A1 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.